Three years after the launch of Cinryze for hereditary angioedema (HAE), sales of the drug are continuing to grow – far surpassing the original peak sales projections, ViroPharma Inc. said during its analyst day presentation Sept. 21. Management also announced that an FDA clinical hold on a subcutaneous version of the drug combined with a product from Halozyme Therapeutics Inc. is lifted and development now can move forward.
ViroPharma Talks Cinryze Sales, EU Launches
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
More from Pricing Debate
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
A Republican think tank suggested variations of the Most Favored Nation and international reference policies in Medicare and Medicaid, as well as tariffs and other trade levers to rebalance drug pricing disparities between US countries and abroad.
Democrats opposed the nomination because they believe Mehmet Oz will not defend Medicaid from spending cuts. His pledge to continue lowering drug costs in Medicare and Medicaid did not offset the concerns.
The UK branded drug industry is calling for adjustments to be made to the UK voluntary scheme framework for branded medicines, after the payment rate increased to 22.9% for 2025. Meanwhile, the generics industry says the scheme is functioning “as intended” and opposes any changes.